Literature DB >> 31402601

Oral lesions and associated factors in breast cancer survivors.

Luísa Comerlato Jardim1,2, Priscila Trindade Flores3,4, Felipe de Araújo Sensever1, Maria do Carmo Dos Santos Araújo4, Cristina Machado Bragança de Moraes3,4, Juares Chiesa5, Raquel Pippi Antoniazzi6.   

Abstract

AIM: To evaluate the prevalence of oral lesions (OL) and associated factors among survivors of breast cancer (BC).
METHODS: A cross-sectional study involving 150 BC survivors was conducted at a public hospital in southern Brazil. Data were collected on socioeconomic aspects, treatment characteristics and oral problems. The decayed, missing and filled teeth index and the occurrence of OL were evaluated. Logistic regression was performed to determine independent variables associated with the outcome.
RESULTS: 24% of the women had at least 1 OL and 33.3% of these had more than one lesion. Melanotic macule was the most prevalent lesion. Duration of tamoxifen use, radiotherapy, missing teeth and xerostomia were associated with the occurrence of OL (P < .05). In the adjusted analysis, women with more than 13 missing teeth and xerostomia had 2.39-fold (95% confidence interval [CI], 1.06-5.40) and 2.71-fold (95% CI, 1.14-6.42), respectively, greater odds of exhibiting OL.
CONCLUSION: Approximately 1/4 of the BC survivors exhibited OL, which were associated with tooth loss and xerostomia. These findings could assist in the establishment of oral health strategies for women with BC.
© 2019 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  breast cancer; oral health; oral lesion

Mesh:

Year:  2019        PMID: 31402601     DOI: 10.1111/jicd.12447

Source DB:  PubMed          Journal:  J Investig Clin Dent        ISSN: 2041-1618


  1 in total

1.  Association between tamoxifen and tooth loss in women with breast cancer.

Authors:  Felipe de Araujo Sensever; Luísa Comerlato Jardim; Kívia Linhares Ferrazzo; Jovito Adiel Skupien; Raquel Pippi Antoniazzi
Journal:  Support Care Cancer       Date:  2022-07-07       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.